Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry
United European Gastroenterology Journal · 2026-05 · 14 (4)
DOI: 10.1002/ueg2.70223 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 30.04.2026. Verfasst von M Iborra und 51 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Inflammatory Bowel Disease Research Group, Health Research Institute La Fe (IIS La Fe), IBD Unit, La Fe University and P…. Hauptthemen laut MEDLINE: Crohn Disease, Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
Methods
Multicenter observational study including patients with CD who received UPA, using data from a nationwide registry. Patients were classified according to active luminal disease, extraintestinal manifestations (EIMs), or combination therapy with another biological therapy. Disease activity was assessed using the Harvey–Bradshaw Index (HBI), C‐reactive protein (CRP), and fecal calprotectin (FC) at baseline and weeks 12, 24, and 52. Endoscopic outcomes were evaluated when available. Adverse events (AEs), hospitalizations, and treatment discontinuations were recorded.
Results
300 patients were included, representing a highly treatment‐refractory population, with 98% previously exposed to anti‐TNF agents and 59% to three or more advanced therapies. In those treated for active luminal disease, corticosteroid‐free clinical remission was achieved in 60%–62% of patients at weeks 12, 24 and 52. CRP normalization increased from 64% at week 12%–74% at week 52, while FC normalization improved from 48% to 64%. Patients treated for EIMs achieved high and sustained remission rates with excellent treatment persistence. Early remission at week 12 was strongly associated with sustained remission and meaningful endoscopic improvement. UPA was discontinued in 98 patients (39%). AEs were reported in 71 patients (24%).
Conclusions
In this large real‐world cohort, UPA demonstrated sustained clinical and biochemical effectiveness, meaningful endoscopic response, and a safety profile consistent with clinical trial data. Early response emerged as a key predictor of long‐term outcomes, supporting the clinical utility of UPA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Inflammatory Bowel Disease Research Group, Health Research Institute La Fe (IIS La Fe), IBD Unit, La Fe University and Polytechnic Hospital, Valencia, Spain.
- Health Research Institute La Fe, Valencia, Spain.
- Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
- La Paz University Hospital, Universidad Autónoma de Madrid, Hospital La Paz Institute for Health Research, La Paz Hospital, Madrid, Spain.
- Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
- Universidad de Las Palmas de Gran Canaria (ULPGC), Las Palmas de Gran Canaria, Spain.
ORCID-Profile: M Iborra, M D Martín-Arranz, A Garrido, E Brunet-Mas, J P Gisbert, I Ordás, F Argüelles-Arias, R Vicente-Lidón, J M Paredes, M Barreiro-de Acosta, J M Huguet, M J García, A Gutiérrez-Casbas, L Ramos, M Calafat, C Suárez-Ferrer, A Mínguez, A Mancebo, Alejandro Hernández-Camba, C Rodríguez-Gutiérrez, M Chaparro, E Ricart, L Almenara-Michelena, E Domènech, P Nos
Zitieren
APA
Iborra, M., Botella, B., Martín-Arranz, M. D., Ceballos, D., Martínez-Pascual, C., Garrido, A., Varela, P., Moreta, M., Brunet-Mas, E., González-Lama, Y., Rodríguez-González, E., Vicuña, M., Gisbert, J. P., Ordás, I., Argüelles-Arias, F., Tosca-Cuquerella, J., Vicente-Lidón, R., Sierra-Ausín, M., Rodríguez-Lago, I., …, & Nos, P. (2026). Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry. United European Gastroenterology Journal, 14(4). https://doi.org/10.1002/ueg2.70223
Vancouver
Iborra M, Botella B, Martín-Arranz MD, Ceballos D, Martínez-Pascual C, Garrido A, et al. Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry. United European Gastroenterology Journal. 2026;14(4). doi:10.1002/ueg2.70223
BibTeX
@article{Iborra2026,
author = {Iborra, M and Botella, B and Martín-Arranz, M D and Ceballos, D and Martínez-Pascual, C and Garrido, A and Varela, P and Moreta, M and Brunet-Mas, E and González-Lama, Y and Rodríguez-González, E and Vicuña, M and Gisbert, J P and Ordás, I and Argüelles-Arias, F and Tosca-Cuquerella, J and Vicente-Lidón, R and Sierra-Ausín, M and Rodríguez-Lago, I and Martín-Rodríguez, D and Paredes, J M and Sicilia, B and García de la Filia, I and Jiménez, N and Barreiro-de Acosta, M and Betoré, E and Ferrer-Bradley, I and García-Alles, L and Huguet, J M and Castellet-Farrús, S and García, M J and Gutiérrez-Casbas, A and Ponferrada-Díaz, Á and Ramos, L and Calafat, M and Vera, I and Suárez-Ferrer, C and Fernández-Velado, E and Rodríguez-Sánchez, S and Mínguez, A and Mancebo, A and Barrio, J and Lario, S and de La Cruz, D R and Hernández-Camba, Alejandro and Rodríguez-Gutiérrez, C and Chaparro, M and Ricart, E and Almenara-Michelena, L and Balaguer, A and Domènech, E and Nos, P},
title = {Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {4},
doi = {10.1002/ueg2.70223}
}
EUVIMED